MedTrace Logo

Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients

NCT05933031 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 381

Last updated 2023-07-06

No results posted yet for this study

Summary

This exploratory study is designed to compare safety and efficacy between a Tegoprazan dose-specific standard triple therapy and Lansoprazole standard triple therapy in H. pylori positive patients.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Tegoprazan 50 mg Triple Therapy

Tegoprazan 50 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days

DRUG

Tegoprazan 100 mg Triple Therapy

Tegoprazan 100 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days

DRUG

Lansoprazole Triple Therapy

Lansoprazole/Clarithromycin/ Amoxicillin BID peroral, 14 days

Sponsors & Collaborators

  • HK inno.N Corporation

    lead INDUSTRY

Principal Investigators

  • Jae Gyu Kim · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-27
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05933031 on ClinicalTrials.gov